An Alternative Non‐Macrolide, Non‐Imidazole Treatment Regimen for Curing Helicobacter pylori and Duodenal Ulcers: Ranitidine Bismuth Citrate Plus Amoxicillin
Authors:
- H. The Rbc PyloriHPH. The Rbc Pylori
- Study GroupSGStudy Group
- 1 June 1998
- journal article
- clinical trial
- Published by Wiley in Helicobacter
- Vol. 3 (2) , 125-131
Abstract
Background. Because patients who fail to be cured of H. pylori infection following macrolide or imidazole therapy are difficult to treat, there is a clear need for a reasonably effective and simple second‐line treatment regimen. The purpose of these two studies was to evaluate the efficacy of ranitidine bismuth citrate (RBC) plus amoxicillin for the cure of H. pylori infection and for healing duodenal ulcers and preventing ulcer relapse. Materials and Methods. Two identically designed randomized, double‐blind, double‐dummy studies were conducted in patients with an H. pylori‐associated duodenal ulcer. Patients were treated with either RBC 400 mg bid for 4 weeks plus amoxicillin 500 mg qid for 2 weeks, RBC 400 mg bid for 4 weeks and placebo qid for 2 weeks, placebo bid for 4 weeks and amoxicillin 500 mg qid for 2 weeks, or placebo bid for 4 weeks and placebo qid for 2 weeks. Patients with healed ulcers after 4 weeks of treatment were eligible for entry into a 24‐week observation phase for the assessment of H. pylori status (culture, histology, and CLOtestTM) and ulcer relapse. Results. A total of 229 patients with confirmed H. pylori infection at baseline were evaluated. Of these, 132 whose ulcers had healed entered the 24‐week posttreatment observation phase. The combination of RBC plus amoxicillin resulted in higher H. pylori cure rates (55%) and higher duodenal ulcer healing (74%) than did either treatment alone. All treatments were well tolerated. Conclusions. The combination of ranitidine bismuth citrate plus amoxicillin cures H. pylori infection in more than half of the patients treated. This treatment regimen shows promise as the basis for future non‐macrolide, non‐imidazole triple therapy regimens for curing H. pylori infection. Such regimens may be appropriate second‐line treatment for patients who are resistant to or who are unable to tolerate macrolide‐ or imidazole‐containing therapies.Keywords
This publication has 18 references indexed in Scilit:
- GR122311X (ranitidine bismuth citrate) a new drug for the treatment of gastric ulcerGastroenterology, 1995
- Treatment of Peptic Ulcers Caused by Helicobacter pyloriNew England Journal of Medicine, 1993
- Results of a multicentre European survey in 1991 of metronidazole resistance inHelicobacter pyloriEuropean Journal of Clinical Microbiology & Infectious Diseases, 1992
- Helicobacter pylori and duodenal ulcerDigestive Diseases and Sciences, 1992
- Helicobacter pyloriand Peptic Ulcer DiseaseNew England Journal of Medicine, 1991
- Metronidazole resistance in Helicobacter pyloriThe Lancet, 1990
- Pathogenesis of Peptic Ulcer and Implications for TherapyNew England Journal of Medicine, 1990
- PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORIThe Lancet, 1988
- Problems with Clinical Trials on Campylobacter pyloriJournal of Clinical Gastroenterology, 1988
- Single nocturnal dose of an H2 receptor antagonist for the treatment of duodenal ulcer.Gut, 1983